alpidem sold brand name ananxyl nonbenzodiazepine anxiolytic medication briefly used treat anxiety disorders longer previously marketed france discontinued due liver alpidem taken side effects alpidem include sedation fatigue dizziness headache among much less impact cognition memory psychomotor function relative similarly rebound anxiety withdrawal symptoms observed rarely alpidem cause serious liver toxicity including liver failure alpidem nonbenzodiazepine imidazopyridine family structurally related zdrug acts gabaa receptor positive allosteric modulator benzodiazepine site receptor contrast zolpidem however alpidem anxiolytic effects rather sedative hypnotic effects normal therapeutic alpidem first described introduced medical use france also development use countries development discontinued drug never marketed alpidem withdrawn market france due liver alpidem approved treatment generalized anxiety disorder possibly also anxiety clinical studies including patients conducted europe studying alpidem treatment clinical trials alpidem demonstrated effectiveness treatment chronic situational anxiety including stressrelated anxiety generalized anxiety adjustment disorder situational depression also showed preliminary effectiveness institutionalized individuals chronic psychosis high anxiety effectiveness alpidem panic disorder hand understudied anxiolytic effects alpidem described rapid robust maintained situational anxiety anxiolytic effects alpidem onset within hours whereas chronic anxiety disorders effects onset within days indications tolerance anxiolytic effects need dose increases people anxiety taking alpidem improvement mood sleep also anxiolytic effectiveness alpidem example measured reductions hamilton anxiety rating scale hama superior placebo comparable equivalent benzodiazepines including diazepam mgday lorazepam mgday clorazepate mgday directly comparative randomized controlled alpidem also directly compared buspirone mgday generalized anxiety relative buspirone found produce rapid improvement significantly greater effectiveness fewer side effects lower discontinuation recommended dose alpidem mg total per day given single doses mg two three times per alpidem provided form oral alpidem described side effects include sedation dosedependent fatigue dizziness headache among reported minimal sedative effects virtually negative effects cognition memory psychomotor function therapeutic however impairment vigilance psychomotor function reported high doses addition driving ability studied alpidem found central side effects alpidem found worse elderly people young alpidem alter sleep architecture measured laboratory tests patients treated alpidem showed adverse effects cardiovascular respiratory function seen clinical rebound anxiety withdrawal symptoms observed alpidem abrupt discontinuation following weeks months conversely substantial withdrawal symptoms including rebound anxiety observed side effects alpidem described quite different directly comparative trials alpidem produced similar anxiolytic effects less fatigue asthenia depressive mood psychomotor impairment benzodiazepines rates somnolence drowsiness comparable benzodiazepines described milder whereas benzodiazepines commonly produce dizziness muscle weakness fatigue sleepiness side effects prominent adverse effects doses alpidem similar anxiolytic lack withdrawal rebound symptoms alpidem upon discontinuation also contrast addition alpidem significantly antagonized amnestic effects lorazepam showed similar trends cognitive measures clinical study two drugs combined assessed following marketing authorization france several cases severe liver toxicity reported people taking resulted one death several cases liver result alpidem soon withdrawn liver toxicity alpidem subsequently characterized preclinical may related interactions alpidem translocator protein tspo present high amounts liver may mediate toxic effects little information available overdose doses high mgday times recommended total daily dose assessed clinical alpidem may interact alcohol lesser extent alpidem gabaa receptor positive allosteric modulator specifically acting agonist benzodiazepine site receptor complex formerly known central benzodiazepine receptor addition affinity benzodiazepine site gabaa receptor ki nm alpidem similarly high affinity translocator protein tspo formerly peripheral benzodiazepine receptor pbr ki alpidem shows selectivity subunitcontaining gabaa receptors subunitcontaining gabaa selectivity subunitcontaining gabaa receptors subunitcontaining gabaa however alpidem also described potently modulating subunitcontaining gabaa receptors effect subunitcontaining gabaa findings appear mixed whether alpidem partial agonist full agonist benzodiazepine site gabaa animals alpidem anxiolyticlike effects models weak anticonvulsant effects weak sedative amnesic ataxic muscle relaxant high doses alpidem antagonize sedative muscle relaxant effects diazepam flumazenil shown antagonize anxiolytic anticonvulsant effects alpidem besides acting directly via gabaa receptor interactions tspo might also contribute anxiolytic effects protein mediates promotion neurosteroidogenesis brain instance alpidem structurally related zolpidem alpidem zolpidem gabaa receptor positive allosteric modulators benzodiazepine site preference subunitcontaining alpidem zolpidem low affinity subunitcontaining gabaa receptors contrast similarly alpidem zolpidem selective subunitcontaining gabaa receptors low affinity subunitcontaining gabaa receptors contrast zdrugs alpidem high affinity tspo zolpidem low affinity affinity alpidem tspo also previously known highest drug although benzodiazepines like diazepam also known bind tspo affinity alpidem protein least higher whereas zolpidem shows hypnotic sedative effects used treat insomnia alpidem shows mainly anxiolytic effects used treat anxiety alpidem developed widespread use recombinant gabaa hence pharmacological profile gabaa receptors including profile different subpopulations receptors never fully pharmacodynamic mechanisms underlying anxioselective anxiolyticselective profile alpidem gabaa receptor positive allosteric modulator case subtype selectivity different populations gabaa receptors partial agonism benzodiazepine site gabaa receptor andor interactions tspo may potentially although anxioselective profiles observed many gabaa receptor positive allosteric modulators preclinical research alpidem gabaa receptor positive allosteric modulator anxioselective effects unambiguously demonstrated human clinical ocinaplon also shown preliminary signs anxioselective profile clinical studies development agent discontinued latestage trials due findings elevated liver enzymes small subset gabaa receptor positive allosteric modulators selectivity subunitcontaining gabaa receptors subunitcontaining gabaa receptors instance adipiplon others investigation potential anxioselective however drugs yet completed clinical development marketed medical despite many developmental failures alpidem serves potential proof concept anxioselective gabaa receptor positive allosteric modulators may however interactions tspo key anxiolytic effects alpidem may actually alpidem taken via oral absorption alpidem rapid reaches peak levels overall bioavailability estimated approximately precise value absolute bioavailability absorption alpidem indicated peak areaunderthecurve levels linear across dose range food increases bioavailability alpidem alpidem highly lipophilic compound animals extensively distributed lipidrich similarly alpidem shown cross barrier animals showed brainplasma ratio following systemic related significantly slower efflux alpidem brain active metabolites alpidem also brainpenetrant although occur brain levels lower alpidem may concentrated lipidrich white matter brain structures grey matter humans volume distribution alpidem large plasma protein binding alpidem similar isolated fractions bound albumin glycoprotein free fraction alpidem slightly higher people cirrhosis renal failure relative normal individuals alpidem extensively metabolized including hydroxylation dealkylation many metabolites alpidem identified metabolites may contribute pharmacological alpidem eliminated mainly feces less excreted majority alpidem eliminated within hours following oral trace amounts unchanged alpidem found feces metabolites alpidem excreted mainly via bile feces less eliminated via elimination halflife alpidem mean hours range hours following single oral dose given young elderly individuals trend toward longer halflife observed conversely children age years halflife alpidem considerably reduced halflives alpidem metabolites significantly prolonged people hepatic conversely halflives alpidem metabolites unchanged people different stages renal impairment though plasma concentrations significantly clearance alpidem estimated healthy alpidem nonbenzodiazepine hence structurally related member imidazopyridine group alpidem structurally related zdrug zolpidem also alpidem developed synthélabo recherche subsequently sanofisynthélabo developed code name sl first described literature alpidem introduced medical use france also undergoing development use countries united states european countries like germany netherlands drug reached phase clinical trials however development united states halted due divergent development countries discontinued alpidem withdrawn market france due liver never marketed alpidem generic name drug inntooltip international nonproprietary name usantooltip united states adopted name bantooltip british approved name dcftooltip dénomination commune developmental code name alpidem sl alpidem previously marketed brand name alpidem previously marketed france longer available httpsenwikipediaorgwikialpidem